Research Library

Federal marijuana legalization is on the horizon — and it’s time for the DEA to get behind the policy changes and move on to fighting more dangerous drugs, writes nonresident fellow Gary Hale.

Among his 2024 Democratic challengers, Biden has the clearest foreign policy record — but it may be difficult to maintain his current balancing act on Ukraine and China when it comes to the general election, writes Bonner Means Baker Fellow Joe Barnes.

Considering the dangers of advanced AI and AI-enhanced social media, there is an urgent need to design neuroscience-based policies to support citizens in building a system of digital self-defense. Enter the “Neuroshield.”

Decades of bad policy have heightened the risks of drug use and created barriers to treatment. And while some states are now trying to reduce the harms caused by the drug war, Texas is doubling down on ineffective policies.

Two new bills introduced in the Texas Legislature could jeopardize the care received by Medicaid patients, writes Vivian Ho, the James A. Baker III Institute Chair in Health Economics. She explains why the legislation would weaken county-owned insurance plans and raise Texans’ tax bills.

The rapid adoption of telemedicine is one of the few positive developments of the COVID-19 pandemic, writes fellow Katharine Neill Harris. She explains why the DEA’s recent proposal to change the rules for prescribing drugs via telemedicine would harm patients and increase demand for and exposure to unregulated and more dangerous drugs.

Gas stoves are a leading source of hazardous indoor air pollution, but they emit only a tiny share of the greenhouse gases that warm the climate. Why, then, have they assumed such a heated role in climate politics?

In 2022, the nation faced fundamental questions about how we govern our economy and society — particularly how we formulate public policy. Here, we share 10 highlights of our work that illustrate our impact from the previous year.

Drug companies that bypass distributors and offer generics directly to patients, like the Mark Cuban Cost Plus Drug Company, could disrupt the pharmaceutical supply chain and ultimately save thousands of lives.